东方生物(688298.SH)发预亏，预计2025年年度归母净亏损5.23亿元

Core Viewpoint - Dongfang Bio (688298.SH) is expected to report a net loss of 523 million yuan for the fiscal year 2025, attributed to significant investments in technology platform development, foreign exchange losses, reduced interest income contributions, and increased asset depreciation and impairment losses [1] Group 1: Financial Performance - The company anticipates a net profit attributable to shareholders of the parent company to be -523 million yuan for 2025 [1] - The main business of the company continues to develop steadily despite the projected loss [1] Group 2: Contributing Factors - The overall cultivation period for strategic development across various industrial technology platforms has led to substantial ongoing investments [1] - Foreign exchange losses and a decrease in contributions from interest income have negatively impacted profits [1] - The company has also incurred increased asset-related depreciation and impairment losses [1]